Pharmacology

OST-HER2 could be a frontline treatment for dogs and humans

The STAY study is investigating LOY-002, a therapy designed by Loyal to extend healthy lifespans in canines

The FDA has approved the new indication for Zoetis' Simparica Trio

Treating separation anxiety requires behavioral modification and medication, but which drug should you choose?

The entire hive can be treated for common bacterial diseases

Current levels of pain management administration by dairy producers and veterinarians in Europe and North America are low.

Felixvet has introduced a carprofen therapy with the same therapeutic benefits as Rimadyl

Communications expert Wendy S. Myers provides scripts for confident client conversations

Zoetis has launched its’ 0.5 mL dose for intranasal Vanguard B

Longevity drug developer Loyal and pain therapy manufacturer Elanco Animal Health are working with the organization to promote the need for aging canine care and enhance veterinary resources.

William Murphy, PhD, BS, was selected by SEC provosts for the recognition, from among 16 previous achievement award recipients

Felycin-CA1 manages ventricular hypertrophy in feline patients with subclinical hypertrophic cardiomyopathy

DuOtic received FDA approval March 2024 to treat canine patients

These natural and pharmaceutical therapies aid by reducing the reabsorption of sodium and water

Rachel Venable, DVM, MS, DACVIM (Oncology) discussed what primary doctors can do to treat their patients with cancer when clients decline specialty care during a WVC 2025 CE session

Loyal’s developmental therapy aims to increase longevity and quality of life for senior dogs

The novel therapy is the first drug for treating cats with hypertrophic cardiomyopathy

American Regent Animal Health created the new resources in collaboration with the UC-Davis professor Denis Marcellin-Little, DEDV, DACVS, DACVSMR, DECVS

Most major sections of the new animal drug application for Laverdia-CA1 have been deemed complete by the FDA, bringing the drug closer to approval

Approved by the FDA in January 2024, EquiCoxib is a noninvasive, liquid formulation.

The legislation seeks to empower law enforcement and fight the opioid epidemic while also protecting access to the drug for veterinary use

Vetigenics is seeing encouraging results of a completed study for an antibody aimed at treating oral melanoma in dogs, used in combination with palliative radition.

Librela (bedinvetmab injection) is a monthly injectable monoclonal antibody, for which real-world drug experience data has been collected in the past year.

Revelation Animal Health, part of the compounding pharmacy network Revelation Pharma, will debut at the 2025 VMX event in Orlando, Florida.

At VMX, Virbac is launching an oral product featuring ursolic acid, in collaboration with Emmyon Inc.

Indications are broadened for Zoetis products to include new protections against Asian longhorned ticks and tapeworms

Integrative therapies can enhance a patient’s survival and quality of life

Neurologic signs were reported with bedinvetmab injection use in dogs

dvm360 is counting down the Top 20 news stories and articles from 2024 with this series of spotlights